Multiple Myeloma Enrichment SNP Microarray−Oncology (Reveal®)
Use
This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.
Special Instructions
Clinicians are requested to provide the patient's clinical history and details of any ancillary oncology testing. For any inquiries, customer service can be reached at 800-345-4363.
Limitations
The SNP assay does not detect balanced rearrangements, low-level mosaicism (below 10%), marker chromosomes consisting only of heterochromatin, or cases of tetraploidy. The test was developed by Labcorp with performance characteristics determined by the lab itself. It has not received clearance or approval from the Food and Drug Administration (FDA).
Methodology
Microarray
Biomarkers
LOINC Codes
- 31208-2
- 62357-9
- 62365-2
- 48672-0
- 11502-2
Result Turnaround Time
11-15 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL bone marrow
Minimum Volume
1 mL bone marrow for array only
Container
Green-top (heparin) tube (preferred) or lavender-top (EDTA) tube
Collection Instructions
Using sterile technique, collect 2 mL of bone marrow into a heparin (EDTA) tube or syringe. Invert the tube several times to prevent coagulation. Specimens should be sent the same day as collected.
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Upon receipt, suitability of specimen will be determined by the Cytogenetics laboratory.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 days |